1-(4-甲氧基苯基)-2,5-二甲基-1H-吡咯-3-羧酸 | 3807-58-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 中文名称: 1-(4-甲氧基苯基)-2,5-二甲基-1H-吡咯-3-羧酸
• 英文名称: 1-(4-Methoxy-phenyl)-2,5-dimethyl-4-carboxy-pyrrol
• 英文别名: 1-(4-methoxyphenyl)-2,5-dimethyl-1H-pyrrole-3-carboxylic acid；1-(4-methoxyphenyl)-2,5-dimethylpyrrole-3-carboxylic acid
• CAS: 3807-58-7
• 化学式: C₁₄H₁₅NO₃
• mdl: MFCD03848152
• 分子量: 245.278
• InChiKey: JPCJXGCPGGBFCU-UHFFFAOYSA-N

物化性质

• 沸点：
  424.7±45.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.214
• 拓扑面积：
  51.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  4-二甲基氨基甲基苄胺 、 1-(4-甲氧基苯基)-2,5-二甲基-1H-吡咯-3-羧酸 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以26%的产率得到N-(4-((dimethylamino)methyl)benzyl)-1-(4-methoxyphenyl)-2,5-dimethyl-1H-pyrrole-3-carboxamide
  参考文献：
  名称：

  Novel pyrrole- and 1,2,3-triazole-based 2,3-oxidosqualene cyclase inhibitors

  摘要：

  Pyrrole- and 1,2,3-triazole-based 2,3-oxidosqualene cyclase (OSC) inhibitors 3 and 4 were discovered by conducting a virtual screening, a docking study based on the crystallographic structure of OSC, and biological assays. The hit rate of the assays was increased by establishing appropriate substructural filters in the virtual screening stage. Amide derivatives of 8 and 12 preserved the inhibitory activity of parent compound 3, which provided a reasonable starting point for further structure-activity-relationship (SAR) studies on related compounds. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.131
• 作为产物：
  描述：

  ethyl 1-(4-methoxyphenyl)-2,5-dimethyl-1H-pyrrole-3-carboxylate 在 水 、 potassium hydroxide 作用下， 以 乙醇 为溶剂， 反应 7.0h， 以65%的产率得到1-(4-甲氧基苯基)-2,5-二甲基-1H-吡咯-3-羧酸
  参考文献：
  名称：

  Novel pyrrole- and 1,2,3-triazole-based 2,3-oxidosqualene cyclase inhibitors

  摘要：

  Pyrrole- and 1,2,3-triazole-based 2,3-oxidosqualene cyclase (OSC) inhibitors 3 and 4 were discovered by conducting a virtual screening, a docking study based on the crystallographic structure of OSC, and biological assays. The hit rate of the assays was increased by establishing appropriate substructural filters in the virtual screening stage. Amide derivatives of 8 and 12 preserved the inhibitory activity of parent compound 3, which provided a reasonable starting point for further structure-activity-relationship (SAR) studies on related compounds. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.131

文献信息

• PRODRUGS OF INHIBITORS OF PLASMA KALLIKRIEN
  申请人：Sinha Sukanto

  公开号：US20110152533A1

  公开（公告）日：2011-06-23

  The present invention provides prodrugs of compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating plasma kallikrein dependent diseases or conditions, for example, diabetic macular edema, with the prodrugs having the formula:

  该发明提供了抑制血浆激肽酶（PK）活性的化合物的前体药物，以及预防和治疗血浆激肽酶依赖性疾病或病况的方法，例如糖尿病黄斑水肿，这些前体药物具有以下结构式：
• PRODRUGS OF INHIBITORS OF PLASMA KALLIKREIN
  申请人：ActiveSite Pharmaceuticals, Inc.

  公开号：US20140128436A1

  公开（公告）日：2014-05-08

  The present invention provides prodrugs of compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating plasma kallikrein dependent diseases or conditions, for example, diabetic macular edema, with the prodrugs having the formula:

  本发明提供了抑制血浆卡利肌酶（PK）活性的化合物的前药，并提供了预防和治疗依赖于血浆卡利肌酶的疾病或情况的方法，例如糖尿病黄斑水肿。这些前药的化学式为：
• US8609866B2
  申请人：——

  公开号：US8609866B2

  公开（公告）日：2013-12-17
• US9206123B2
  申请人：——

  公开号：US9206123B2

  公开（公告）日：2015-12-08
• [EN] PRODRUGS OF INHIBITORS OF PLASMA KALLIKREIN<br/>[FR] PROMÉDICAMENTS D'INHIBITEURS DE LA KALLICRÉINE PLASMATIQUE
  申请人：ACTIVESITE PHARMACEUTICALS INC

  公开号：WO2011075684A1

  公开（公告）日：2011-06-23

  The present invention provides prodrugs of compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating plasma kallikrein dependent diseases or conditions, for example, diabetic macular edema, with the prodrugs having the formula (I).